Literatur
- 1
Fonseca V, Rosenstock J, Patwardhan R, Salzman A.
Effect of metformin and rosiglitazone combination therapy in patients with type 2
diabetes mellitus: a randomized controlled trial.
JAMA.
2000;
283
1695-1702
- 2
Jick S S, Stender M, Myers M W.
Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic
agents.
Diabetes Care.
1999;
22
2067-2071
- 3
Lohrke B, Shahi S K, Kruger B, Schmidt P, Renne U, Dietl G.
Thiazolidinedione-induced activation of the transcription factor peroxisome proliferator-activated
receptor gamma in cells adjacent to the murine skeletal muscle: implications for
fibroblast functions.
Pflugers Arch.
2000;
439
288-296
- 4
Scheen A J.
Thiazolidinediones and liver toxicity.
Diabetes Metab.
2001;
27
305-313
- 5
Algenstaedt P, Hamann A.
Glitazone - eine neue Substanzklasse in der Behandlung des Typ-2-Diabetes.
Dtsch Med Wochenschr.
2001;
126
951-952
Dr. Petra Algenstaedt
Dr. A. Hamann
Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf
Martinistraße 52
20246 Hamburg
Telefon: 040/428033960
Fax: 040/428036820
eMail: algensta@uke.uni-hamburg.de
